A Multi-center, Open-labeled Study of the Long-term Safety and Efficacy of Lubiprostone in Patients With Opioid-induced Bowel Dysfunction
Phase of Trial: Phase III
Latest Information Update: 28 Aug 2017
Price : $35 *
At a glance
- Drugs Lubiprostone (Primary)
- Indications Constipation
- Focus Adverse reactions; Registrational
- Sponsors Sucampo Pharmaceuticals
- 28 Aug 2017 Results of post-hoc pooled analysis of this and other 5 studies published in the Digestive Diseases and Sciences.
- 04 Sep 2013 Data will be presented during PAINWeek 2013, according to a Sucampo Pharmaceuticals media release.
- 01 May 2013 New trial record